The proceeds arrive as the company advances its pivotal Phase III MAVERIC trial, which evaluates CardiolRx for the treatment of recurrent pericarditis. CEO David Elsley noted that the capital injection reflects shareholder confidence in the company’s strategic direction and clinical progress. Beyond funding the MAVERIC readout, the company intends to use the funds to support regulatory preparations for a potential New Drug Application and to further develop its pipeline, including the subcutaneous formulation CRD-38.

Simultaneously, Cardiol Therapeutics has issued an acceleration notice regarding the remaining warrants from its October 2025 private placement. Holders have until October 16, 2026, to exercise their options, after which any remaining warrants will be cancelled. With the MAVERIC program already building on positive Phase II results, the company aims to offer a differentiated therapy for patients suffering from the debilitating chest pain and inflammation associated with recurrent pericarditis.